These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 29936534)

  • 1. Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients.
    Segatori VI; Cuello HA; Gulino CA; Albertó M; Venier C; Guthmann MD; Demarco IA; Alonso DF; Gabri MR
    Cancer Immunol Immunother; 2018 Aug; 67(8):1285-1296. PubMed ID: 29936534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody.
    Hernández AM; Toledo D; Martínez D; Griñán T; Brito V; Macías A; Alfonso S; Rondón T; Suárez E; Vázquez AM; Pérez R
    J Immunol; 2008 Nov; 181(9):6625-34. PubMed ID: 18941253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients.
    Alfonso S; Valdés-Zayas A; Santiesteban ER; Flores YI; Areces F; Hernández M; Viada CE; Mendoza IC; Guerra PP; García E; Ortiz RA; de la Torre AV; Cepeda M; Pérez K; Chong E; Hernández AM; Toledo D; González Z; Mazorra Z; Crombet T; Pérez R; Vázquez AM; Macías AE
    Clin Cancer Res; 2014 Jul; 20(14):3660-71. PubMed ID: 24788102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism.
    Hernández AM; Rodríguez N; González JE; Reyes E; Rondón T; Griñán T; Macías A; Alfonso S; Vázquez AM; Pérez R
    J Immunol; 2011 Mar; 186(6):3735-44. PubMed ID: 21300821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racotumomab for treating lung cancer and pediatric refractory malignancies.
    Gabri MR; Cacciavillano W; Chantada GL; Alonso DF
    Expert Opin Biol Ther; 2016; 16(4):573-8. PubMed ID: 26903265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer.
    Gajdosik Z
    Drugs Today (Barc); 2014 Apr; 50(4):301-7. PubMed ID: 24918647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Racotumomab-alum vaccine for the treatment of non-small-cell lung cancer.
    Hernández AM; Vázquez AM
    Expert Rev Vaccines; 2015 Jan; 14(1):9-20. PubMed ID: 25420897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer.
    Segatori VI; Vazquez AM; Gomez DE; Gabri MR; Alonso DF
    Front Oncol; 2012; 2():160. PubMed ID: 23162791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-ganglioside antibodies induced in chickens by an alum-adsorbed anti-idiotype antibody targeting NeuGcGM3.
    Guthmann MD; Venier C; Toledo D; Segatori VI; Alonso DF; Fainboim L; Vázquez AM; Ostrowski H
    Front Immunol; 2012; 3():422. PubMed ID: 23335925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data.
    Vázquez AM; Hernández AM; Macías A; Montero E; Gómez DE; Alonso DF; Gabri MR; Gómez RE
    Front Oncol; 2012; 2():150. PubMed ID: 23110257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I Study of the Anti-Idiotype Vaccine Racotumomab in Neuroblastoma and Other Pediatric Refractory Malignancies.
    Cacciavillano W; Sampor C; Venier C; Gabri MR; de Dávila MT; Galluzzo ML; Guthmann MD; Fainboim L; Alonso DF; Chantada GL
    Pediatr Blood Cancer; 2015 Dec; 62(12):2120-4. PubMed ID: 26154941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human antibodies reactive to NeuGcGM3 ganglioside have cytotoxic antitumor properties.
    Rodríguez-Zhurbenko N; Martínez D; Blanco R; Rondón T; Griñán T; Hernández AM
    Eur J Immunol; 2013 Mar; 43(3):826-37. PubMed ID: 23319307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Racotumomab in Non-Small Cell Lung Cancer as Maintenance and Second-Line Treatment.
    Cáceres-Lavernia HH; Nenínger-Vinageras E; Varona-Rodríguez LM; Olivares-Romero YA; Sánchez-Rojas I; Mazorra-Herrera Z; Basanta-Bergolla D; Duvergel-Calderín D; Torres-Cuevas BL; Castillo-Carrillo C
    MEDICC Rev; 2021; 23(3-4):21-28. PubMed ID: 34516533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-NeuGcGM3 reactivity: a possible role of natural antibodies and B-1 cells in tumor immunosurveillance.
    Rodriguez-Zhurbenko N; Rabade-Chediak M; Martinez D; Griñan T; Hernandez AM
    Ann N Y Acad Sci; 2015 Dec; 1362():224-38. PubMed ID: 26214505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune response to racotumomab in a child with relapsed neuroblastoma.
    Sampor C; Guthmann MD; Scursoni A; Cacciavillano W; Torbidoni A; Galluzzo L; Camarero S; Lopez J; de Dávila MT; Fainboim L; Chantada GL
    Front Oncol; 2012; 2():195. PubMed ID: 23267436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NGcGM3 ganglioside: a privileged target for cancer vaccines.
    Fernandez LE; Gabri MR; Guthmann MD; Gomez RE; Gold S; Fainboim L; Gomez DE; Alonso DF
    Clin Dev Immunol; 2010; 2010():814397. PubMed ID: 21048926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial.
    Neninger E; Díaz RM; de la Torre A; Rives R; Díaz A; Saurez G; Gabri MR; Alonso DF; Wilkinson B; Alfonso AM; Combet T; Pérez R; Vázquez AM
    Cancer Biol Ther; 2007 Feb; 6(2):145-50. PubMed ID: 17218777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine.
    Carr A; Rodríguez E; Arango Mdel C; Camacho R; Osorio M; Gabri M; Carrillo G; Valdés Z; Bebelagua Y; Pérez R; Fernández LE
    J Clin Oncol; 2003 Mar; 21(6):1015-21. PubMed ID: 12637465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Significance of Tumor Tissue NeuGcGM3 Ganglioside Expression in Patients Receiving Racotumomab Immunotherapy.
    Uskent N; Ayla S; Molinas Mandel N; Ozkan M; Teomete M; Baloglu H; Aydıncer C; Yergok H; Dogan E; Berk B; Yazar A
    J Oncol; 2020; 2020():1360431. PubMed ID: 32670370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of anti-Neu-glycolyl-ganglioside antibodies by immunization with an anti-idiotype monoclonal antibody: A self versus non-self-matter.
    Hernández AM; Rodríguez M; López-Requena A; Beausoleil I; Pérez R; Vázquez AM
    Immunobiology; 2005; 210(1):11-21. PubMed ID: 16076030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.